Merck KGaA and Versant Ventures Co-found Saturnus Bio

Merck KGaA (MRK) has partnered with Versant Ventures, a leading U.S. venture capital firm, to co-found Saturnus Bio, a new biotech company focused on developing therapies for genetic cardiomyopathy. Merck KGaA will provide an initial investment of $50 million (USD) in the form of upfront funding and secure a minority stake in Saturnus Bio. This collaboration represents a strategic decision by both companies to closely collaborate from the early stages of research and internalize promising technologies. Additional funding will be provided based on the achievement of preclinical milestones, and Merck KGaA has also secured an exclusive option to fully acquire Saturnus Bio.

Innovative Precision Cardiology through Targeted Gene Modulation

Saturnus Bio is focused on developing novel therapies based on targeted gene modulation for the treatment of rare genetic cardiomyopathies caused by single-gene mutations. These diseases can cause severe structural and functional defects in the heart muscle, leading to heart failure or sudden death. In this collaboration, Merck KGaA plans to combine its armed antibody platform technology with Saturnus Bio's precision cardiology approach to maximize synergy. This approach aims to provide a fundamental treatment by directly targeting the mutated genes, rather than simply alleviating symptoms, which will be a significant turning point for patients and the market.

Implementing a Build-to-Buy Strategy to Strengthen Early-Stage Pipeline

This co-founding follows a typical build-to-buy model, a sophisticated strategy in which a large pharmaceutical company acquires a stake in an early-stage biotech company and secures an acquisition option to diversify development risks. As Danny Bar Zohar, CEO of Merck KGaA's Healthcare division, mentioned in May that the company's early pipeline is somewhat weak, this deal can be interpreted as an immediate measure to strengthen the pipeline. Rick Dewey, an Entrepreneur-in-Residence at Versant and formerly at Regeneron Genetics Center, will lead Saturnus Bio, and Russell Miller, who previously led genetic cardiomyopathy research at Pfizer, will join as co-head of research, further increasing the success rate of new drug development.

Changing Competitive Landscape in the Cardiovascular Disease Treatment Market

The global market for cardiomyopathy treatments is expected to grow rapidly to billions of dollars by 2035, driven by the development of biomarkers and genetic diagnostic technologies. The market is currently dominated by cardiac myosin inhibitors such as mavacamten (Camzyos) from Bristol Myers Squibb (BMS) and aficamten from Cytokinetics. Merck KGaA aims to establish a differentiated and innovative portfolio through Saturnus Bio's targeted gene modulation therapies, rapidly increasing its market share in the cardiovascular market. This joint venture model between a large pharmaceutical company and a specialized VC firm will become a new standard for rapidly and safely advancing promising innovative drug candidates to the clinical stage.